| 0 (0%) | 03-03 10:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 106.75 |
1-year : | 124.69 |
| Resists | First : | 91.4 |
Second : | 106.75 |
| Pivot price | 91.16 |
|||
| Supports | First : | 90.96 |
Second : | 90.69 |
| MAs | MA(5) : | 91.23 |
MA(20) : | 91.14 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1  |
| %K %D | K(14,3) : | 91.5 |
D(3) : | 81.2 |
| RSI | RSI(14): 65.9 |
|||
| 52-week | High : | 91.4 | Low : | 88.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATTR ] has closed below upper band by 1.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 91.46 - 91.91 | 91.91 - 92.28 |
| Low: | 89.91 - 90.53 | 90.53 - 91.04 |
| Close: | 90.37 - 91.31 | 91.31 - 92.07 |
Tue, 03 Mar 2026
FDA releases hold on second of Intellia’s ATTR-CM gene therapy trials - Clinical Trials Arena
Mon, 02 Mar 2026
Intellia's shares rise as FDA hold lifts - FirstWord Pharma
Mon, 02 Mar 2026
Possible treatments for ATTR-CM studied at MUSC, including some with stunning potential - The Medical University of South Carolina
Mon, 02 Mar 2026
Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE Phase 3 Trial for Nexiguran Ziclumeran in ATTR-CM - Quiver Quantitative
Mon, 02 Mar 2026
FDA ends trial halt on 1,200-patient heart disease study - Stock Titan
Thu, 26 Feb 2026
How I Support My Loved One with ATTR-CM: A Personal Story - Healthline
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|